Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Liabilities and Shareholders Equity: 2017-2024

Historic Liabilities and Shareholders Equity for Arcus Biosciences (RCUS) over the last 8 years, with Dec 2024 value amounting to $1.1 billion.

  • Arcus Biosciences' Liabilities and Shareholders Equity fell 25.08% to $974.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 billion, marking a year-over-year decrease of 11.03%. This contributed to the annual value of $1.1 billion for FY2024, which is 5.02% up from last year.
  • According to the latest figures from FY2024, Arcus Biosciences' Liabilities and Shareholders Equity is $1.1 billion, which was up 5.02% from $1.1 billion recorded in FY2023.
  • In the past 5 years, Arcus Biosciences' Liabilities and Shareholders Equity ranged from a high of $1.6 billion in FY2021 and a low of $772.3 million during FY2020.
  • Its 3-year average for Liabilities and Shareholders Equity is $1.2 billion, with a median of $1.1 billion in 2024.
  • Per our database at Business Quant, Arcus Biosciences' Liabilities and Shareholders Equity soared by 280.23% in 2020 and then declined by 18.34% in 2022.
  • Yearly analysis of 5 years shows Arcus Biosciences' Liabilities and Shareholders Equity stood at $772.3 million in 2020, then surged by 106.14% to $1.6 billion in 2021, then fell by 18.34% to $1.3 billion in 2022, then fell by 15.77% to $1.1 billion in 2023, then increased by 5.02% to $1.1 billion in 2024.